Liver steatosis and antiviral therapy in chronic hepatitis C [2]

Liver International

Volumn 27, Issue 2, 2007, Pages 287-

  Testino, Gianni ^a   Sumberaz, Alessandro ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; PEGINTERFERON ALPHA2B; RIBAVIRIN; TRIACYLGLYCEROL; ANTIVIRUS AGENT;

AGE DISTRIBUTION; ANTIVIRAL THERAPY; BODY MASS; CHOLESTEROL BLOOD LEVEL; DIET THERAPY; DISEASE SEVERITY; DRUG BIOAVAILABILITY; DRUG RESPONSE; FATTY LIVER; GENOTYPE; HEPATITIS C; HUMAN; KINESIOTHERAPY; LETTER; LIVER BIOPSY; LIVER HISTOLOGY; LIVER TRANSPLANTATION; OBESITY; RECURRENT INFECTION; SIGNAL TRANSDUCTION; TRIACYLGLYCEROL BLOOD LEVEL; NOTE;

ANTIVIRAL AGENTS; FATTY LIVER; HEPATITIS C, CHRONIC; HUMANS;

EID: 34247622846     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2006.01417.x     Document Type: Letter

References (3)

1. Soresi M, Tripi S, Franco V, et al. Impact of liver steatosis on the antiviral response in the hepatitis C virus-associated chronic hepatitis. Liver Int 2006; 26: 1119-25.
2. Testino G, Sumberaz A, Ravetti G, et al. Pegylated interferon alfa-2b and ribavirin for recurrent hepatitis c after liver transplantation: relationship with steatosis. Digest Liver Dis 2006; 38: 864-5.
3. Walsh MJ, Jonsson JR, Richardson MM, et al. Non response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 in patients with chronic hepatitis C, viral genotype 1. Gut 2006; 55: 529-35.